“Surgical intervention should be performed promptly once even minor symptoms occur.”
–C.M. Otto, University of Washington School of Medicine, Seattle, Washington1
The 2012 ESC/EACTS guidelines for AS recommend replacement for Class I patients, i.e. those with severe AS and symptoms. TAVI is indicated in patients with severe symptomatic AS who are not suitable for AVR as assessed by a “heart team” and should be considered in high risk patients who may still be suitable for surgery, but in whom TAVI is favored by a “heart team” based on the individual risk profile.2 The 2008 ACC/AHA guidelines recommend that AVR should be performed in virtually all symptomatic patients with severe AS. Both guidelines stress that age is not a contraindication to surgery.2,3
Any quotes used in this material are taken from independent third-party publications and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.
Please update to a current version of your preferred browser, this site will perform effectively on the following:Unable to update your browser?
If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility